ARROWHEAD PHARMACEUTICALS, INC. Increase (Decrease) in Other Operating Assets and Liabilities, Net
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) reported Increase (Decrease) in Other Operating Assets and Liabilities, Net of $2.45 million for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet · last filed 2026-08-04
- ARROWHEAD PHARMACEUTICALS, INC. increase (decrease) in other operating assets and liabilities, net for the quarter ending 2026-06-30 was $2.81M, a 6763.41% increase year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. increase (decrease) in other operating assets and liabilities, net for the quarter ending 2026-03-31 was -$385.00K.
- ARROWHEAD PHARMACEUTICALS, INC. increase (decrease) in other operating assets and liabilities, net for the quarter ending 2025-12-31 was $24.00K.
- ARROWHEAD PHARMACEUTICALS, INC. increase (decrease) in other operating assets and liabilities, net for the quarter ending 2025-09-30 was $34.00K, a 97.17% decline year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. increase (decrease) in other operating assets and liabilities, net for fiscal 2025 was -$3.09M, a 357.83% decline from fiscal 2024.
- ARROWHEAD PHARMACEUTICALS, INC. increase (decrease) in other operating assets and liabilities, net for fiscal 2024 was $1.20M.
- ARROWHEAD PHARMACEUTICALS, INC. increase (decrease) in other operating assets and liabilities, net for fiscal 2023 was $0.00.
| Period end | Increase (Decrease) in Other Operating Assets and Liabilities, Net 3 month | Increase (Decrease) in Other Operating Assets and Liabilities, Net 6 month | Increase (Decrease) in Other Operating Assets and Liabilities, Net 9 month | Increase (Decrease) in Other Operating Assets and Liabilities, Net 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-04 | $2.43M derived: sum of 2 quarters · filed 2026-08-04 | $2.45M 10-Q · filed 2026-08-04 | $2.49M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | -$385.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-07 | -$361.00K 10-Q · filed 2026-05-07 | -$327.00K derived: sum of 3 quarters · filed 2026-05-07 | -$286.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $24.00K 10-Q · filed 2026-02-05 | $58.00K derived: sum of 2 quarters · filed 2026-02-05 | $99.00K derived: sum of 3 quarters · filed 2026-08-04 | -$1.67M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-09-30 | $34.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | $75.00K derived: sum of 2 quarters · filed 2026-08-04 | -$1.69M derived: sum of 3 quarters · filed 2026-08-04 | -$3.09M 10-K · filed 2025-11-25 |
| 2025-06-30 | $41.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-04 | -$1.73M derived: sum of 2 quarters · filed 2026-08-04 | -$3.13M 10-Q · filed 2026-08-04 | -$1.93M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | -$1.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-07 | -$3.17M 10-Q · filed 2026-05-07 | -$1.97M derived: sum of 3 quarters · filed 2026-05-07 | -$1.97M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$1.40M 10-Q · filed 2026-02-05 | -$202.00K derived: sum of 2 quarters · filed 2026-02-05 | -$202.00K derived: sum of 3 quarters · filed 2026-02-05 | -$202.00K derived: sum of 4 quarters · filed 2026-02-05 |
| 2024-09-30 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | $1.20M derived: sum of 2 quarters · filed 2025-11-25 | $1.20M derived: sum of 3 quarters · filed 2025-11-25 | $1.20M 10-K · filed 2025-11-25 |
| 2024-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-08-07 | $0.00 derived: sum of 2 quarters · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | |
| 2024-03-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-05-12 | $0.00 10-Q · filed 2025-05-12 | ||
| 2023-12-31 | $0.00 10-Q · filed 2025-02-10 | |||
| 2023-09-30 | $0.00 10-K · filed 2025-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |